Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8670, Japan.
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Esophagus. 2022 Apr;19(2):205-213. doi: 10.1007/s10388-021-00896-0. Epub 2022 Jan 7.
Neoadjuvant chemotherapy (NAC) followed by esophagectomy can improve the prognosis of locally advanced esophageal cancer (LAEC). However, LAEC reportedly recurred in 17-21% of patients within 6 months post surgery. Thus, current treatment strategies may be inadequate for LAECs with poor prognosis. Preoperative identification of patients with poor prognosis might aid in modification of treatment strategies. This study aimed to evaluate the usefulness of the maximum standardized uptake value change rate (ΔSUV) in predicting treatment effects on the primary lesion, prognosis, and LAEC recurrence.
This study involved 220 esophageal cancer patients who underwent esophagectomy after NAC at three facilities in Japan. The optimal cut-off point for ΔSUV in predicting tumor regression grade (TRG) was calculated and used to assess the correlation between ΔSUV and postoperative survival.
The optimal cut-off point for ΔSUV was 0.5. The 5-year overall survival rate in patients with ΔSUV ≥ 0.5 was significantly higher than that in patients with ΔSUV < 0.5 (71.5% vs. 50.5%, P = 0.001). Multivariate analysis identified ΔSUV (hazards ratio, 0.496; P = 0.004) as an independent prognostic factor. Among 199 patients evaluated for recurrence, 24 (12.1%) showed recurrence within 6 months post surgery. Univariate analysis revealed ΔSUV as the only predictor for early recurrence (odds ratio, 0.222; P = 0.004).
ΔSUV before and after NAC is clinically useful as it could help predict TRG, survival outcome, and early recurrence within 6 months post esophagectomy and is easily obtainable in general clinical practice. We believe that it may also help determine suitable treatment strategies for LAEC.
新辅助化疗(NAC)后行食管切除术可改善局部晚期食管癌(LAEC)的预后。然而,术后 6 个月内,LAEC 患者据报道有 17-21%复发。因此,目前的治疗策略可能不足以应对预后不良的 LAEC。术前识别预后不良的患者可能有助于修改治疗策略。本研究旨在评估最大标准化摄取值变化率(ΔSUV)在预测原发肿瘤治疗效果、预后和 LAEC 复发方面的有用性。
本研究纳入了在日本三家医院接受 NAC 后行食管切除术的 220 例食管癌患者。计算了预测肿瘤退缩分级(TRG)的 ΔSUV 的最佳截断点,并评估了 ΔSUV 与术后生存的相关性。
ΔSUV 的最佳截断点为 0.5。ΔSUV≥0.5 的患者 5 年总生存率显著高于 ΔSUV<0.5 的患者(71.5% vs. 50.5%,P=0.001)。多变量分析确定 ΔSUV(风险比,0.496;P=0.004)为独立预后因素。在 199 例评估复发的患者中,24 例(12.1%)术后 6 个月内复发。单因素分析显示,ΔSUV 是早期复发的唯一预测因素(比值比,0.222;P=0.004)。
NAC 前后的 SUV 变化具有临床意义,可帮助预测 TRG、生存结局和术后 6 个月内的早期复发,并且在一般临床实践中易于获得。我们认为,它还可能有助于确定 LAEC 的合适治疗策略。